Carolyn Gombotz Email

Director Regulatory Affairs . Blaze Bioscience

Current Roles

Employees:
34
Revenue:
$4.4M
About
For years, surgeons have been searching for better intraoperative tools to more effectively treat brain cancer. When removing tumors, the ability to precisely identify them is of paramount importance. If too little tissue is removed, cancer cells are left behind to grow and spread. If too much tissue is removed, the patient may experience significant disabilities, including paralysis. Despite advances in intraoperative monitoring and image guidance, postoperative scans sometimes reveal bulky residual tumor that may have been resected safely if surgeons had improved tools to distinguish tumor tissue from normal brain. A team of neurosurgeons, engineers and biologists at the Fred Hutchinson Cancer Research Center and Seattle Children's Hospital Research Institute, led by Dr. Jim Olson, has created a technology that illuminates cancer cells distinguishing tumors from healthy tissue. Tumor Paint technology will enable surgeons to see tumors "live" during surgery giving them a better chance of removing all of the cancerous cells without injuring surrounding healthy tissue.
Blaze Bioscience Address
530 Fairview Ave N
Seattle, WA
United States
Blaze Bioscience Email

Past Companies

Blaze BioscienceDirector of Regulatory Affairs
Blaze BioscienceAssociate Director of Regulatory Affairs
Blaze BioscienceAssociate Director, Clinical Development

#1 Startup Dataset

Growth rates, revenue data, direct competitors and contact details.